Group News

The Center for Liver Disease and Transplantation at NYP/Columbia has created a new program to help pediatric liver transplant patients transition to adult care.
Read More >
The Center for Liver Disease and Transplantation (CLDT) in collaboration with pediatric surgery at NYP/Columbia is making noteworthy advances in the care of children with serious liver conditions, and is a national leader in this field. “Our superior outcomes are the result of unique surgical training, high patient volume, and unsurpassed multidisciplinary collaboration,” says Jean C. Emond, MD, Chief of Transplantation Services at Columbia. “The CLDT brings together leading experts hepatobiliary surgery, hepatology, gastroenterology, oncology, radiology, diagnostic testing and pathology to provide exceptional patient care.”
Read More >
Nonalcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver disease in the United States, affecting 25% of the population. Without intervention, it can lead to significant liver damage in a smaller group of those patients.
Read More >
Non-alcoholic Fatty Liver Disease (NAFLD) is now the most common cause of liver disease among children. Undetected and untreated, it can lead to significant liver injury. To meet the needs of patients, and to serve a growing number of referrals, NYP Morgan Stanley Children’s Hospital has created a dedicated clinic for the study and management of this condition.
Read More >
Surgeons at NYP Morgan Stanley Children’s Hospital have the highest success rate in the nation for primary repair of biliary atresia (BA), a congenital defect that causes bile to back up into the liver, usually resulting in the need for a liver transplant within the first two years of a child’s life. And in cases where a transplant is needed, our transplantation team has made great strides with living donors.
Read More >
Blog & Newsletter

Advances in Curing Hepatitis C

Treat and be Proactive.
Read More >
Trillions of bacteria, fungi, and viruses live inside the human body. Some aid in digestion while others promote a healthy immune system. When these microbes get out of balance, this can set the stage for disease.
Read More >
New antiviral therapies for Hep C are eliminating complications and producing better than 90 percent cure rates, says Lorna Dove, MD, MPH, a hepatologist at Columbia’s Center for Liver Disease and Transplantation. In the past clinicians used to “watch and wait” carefully monitoring the patients to see if they would fall into the 25% who develop fibrosis, and the smaller percentage who progress to liver cancer. “In the past, drugs for this virus were hard to take and we weren’t sure how well they would work in different populations. As a result, many individuals felt they were living with time bomb and in the meantime, worried that they might transmit Hep C to their loved ones.
Read More >
The Adult Small Bowel Program at NYP/Columbia University is making advances in managing patients with intestinal and multivisceral transplants.
Read More >

Pages